Kornimate/medical-research-clean huggingface dataset:
evaluating the impact of vocal health education on mask-wearing workers during covid-19

Conditions: Health Behavior

Summary: the purpose of this clinical trial is to understand how viewing educational health modules impacts vocal health behaviors in mask-wearing healthcare workers.

results of the investigators' previous work showed that mask-wearing healthcare workers have difficulty with voice and communication. healthcare workers reported significant increases in vocal effort and dyspnea while wearing masks, and showed greater effort and poorer vocal quality at the end of the workday compared to the beginning of the day. despite these negative changes, very few healthcare workers reported using any type of communication strategy (e.g., taking breaks, using gestures). therefore, the investigators developed educational modules to address the voice and communication problems facing this population. this clinical trial plans to evaluate how these educational modules impact subjective/objective voice and communication measures in mask-wearing healthcare workers.

Eligibility criteria:
inclusion criteria: * english speaker * occupational voice user who is required to wear a mask at work exclusion criteria: * history of neurological disorder or disease * history of head/neck cancer * current speech, language, voice, or hearing problem/disorder * currently sick or have been sick within the last 14 days, or is waiting on a covid-19 test result

Keywords: voice communication
cologne register of wearable defibrillator (crwd)

Conditions: Myocardial Infarction; Ventricular Dysfunction; Myocarditis

Summary: the wearable cardiac defibrillator (wcd) is an alternative to the implantation of cardioverter defibrillator (icd) for patients at high risk for sudden cardiac death (mostly bridging therapy). the cologne register of wearable defibrillator (crwd) is a prospective register for all patient with an indication of wearable defibrillator.


Eligibility criteria:
inclusion criteria: * adult patients with an indication for wearable defibrillator exclusion criteria: * childs
a trial of lipitor (atorvastatin) for the treatment of polycystic ovary syndrome (pcos) in women with elevated low-density lipoprotein (ldl) cholesterol

Conditions: Polycystic Ovary Syndrome

Summary: the purpose of this study is to determine the efficacy of lipitor (atorvastatin) for the treatment of pcos with elevated ldl cholesterol.

the investigators hypothesize that improving the lipid profile with atorvastatin will improve vascular function, increase the frequency of ovulation, decrease androgen levels, improve insulin sensitivity, and improve the lipid profile more efficiently than placebo.

Eligibility criteria:
inclusion criteria: women with pcos * 8 or fewer menstrual periods per year * elevated serum total testosterone * elevated ldl cholesterol exclusion criteria: * current pregnancy or breastfeeding * current use of oral contraceptives, progestins * insulin sensitizing medications * thyroid disease, hyperprolactinemia, active liver disease, type 1 or type 2 diabetes

Keywords: polycystic ovary syndrome
corticosteroid therapy for severe community-acquired pneumonia

Conditions: Community Acquired Pneumonia

Summary: the purpose of the present study is to assess the efficacy of methylprednisolone as an adjuvant therapy in patients with severe community-acquired pneumonia (cap) (psi 4-5). the hypothesis of the study is that methylprednisolone can decrease the mortality of severe cap without any significant side effects,with reduction of the time to clinical stability and failure rate of treatment.


Eligibility criteria:
inclusion criteria: * community-acquired pneumonia * psi score：4-5 * with at least one of following conditions：①crp ≥150 mg/l,②oxygen index ≤250 , ③bilateral or multi-lober infiltrates in chest image,④ area of pulmonary infiltrates increase \>50% with 48 hous,⑤fever higher than 39℃ exceed 72 hours exclusion criteria: * nosocomial pneumonia * aspiration pneumonia * acute burn injury * gastrointestinal bleeding within the past three months * uncontrolled diabetes mellitus * pregnant or breast feeding * a condition requiring treatment with greater than 0.5 mg/kg/d of prednison or its equivalent * severe immunosuppression (human immunodeficiency virus infection, immunosuppressive conditions or medications) * active tuberculosis * preexisting medical condition with a life expectancy of less than 3 months
intestines and liver contribution to fasting postprandial hypertriglyceridemia

Conditions: Hypertriglyceridemia; Metabolic Syndrome

Summary: fasting and postprandial hypertriglyceridemia (htg) depends on increased production of intestinal triglyceride rich lipoproteins in patients with isolated fasting hypertriglyceridemia. the objective of this study is to compare the serum apob48 rate after a standardized load test, among patients with isolated hypertriglyceridemia and patients with metabolic syndrome.

two major studies in 2007 showed that the occurrence of myocardial infarction and death was more frequent in subjects with the highest "non-fasting" triglycerides level. this is an important point that supports the hypothesis that the development of atheromatous lesions also depends on "remnant" of triglyceride-rich lipoproteins (trl) products such as chylomicrons in the intestine. the elevation of triglycerides in postprandial period depends on the intestinal production of trl that can be excessively increased as has been shown in diabetes. accordingly, it is necessary to distinguish between hepatic and intestinal production of trl in hypertriglyceridemic patients particularly during postprandial period. trl contain a single molecule of apolipoprotein b (apob), apob100 when produced by the liver or apob-48 when they are produced by the gut. it is well known that apo b100 is the lipoprotein of the vldl which is increased in hypertriglyceridemia. but preliminary works showed that fasting concentrations of apob48 were correlated with triglycerides in some hypertriglyceridemic patients. these results suggest an intestinal part in fasting triglycerides levels. it therefore appears that the liver and intestine contribute to hypertriglyceridemia, but the intestinal part is not established particularly in isolated hypertriglyceridemia. the detection of abnormalities in the production of lrt would consider intestinal bowel as a target organ for the initiation of specific lipid-lowering therapy.

Eligibility criteria:
inclusion criteria : 1. patient who provided his consent in writing before the completion of any procedure related to the protocol 2. patient affiliated to the french social security system or to another similar insurance 3. men and women aged from 18 years to 75 years 4. patient of department of endocrinology-metabolism and hospitalized for a medical checkup 5. fasting hypertriglyceridemia \>1.5 g / l 6. no lipid-lowering treatment or omega 3 7. patients with an untreated systolic blood pressure \<130mmhg and diastolic \<85mmhg 8. stable weight (variation less than 5 kg in the month before inclusion) inclusion in the metabolic syndrome group if : * fasting glucose \> 5.6 mmol / l but \<7.0 mmol / l and * waist perimeter \>94 cm in men and \>80cm in women. inclusion in isolated hypertriglyceridemia group: patients not having the criteria of the group "metabolic syndrome" exclusion criteria : 1. diabetic patient 2. any recent changes (less than one month) of any treatment 3. patient participating in another clinical study

Keywords: postprandial test metabolic syndrime htg
impact of operative positioning on the development of shoulder pain after pulmonary lobectomy by vats

Conditions: Post-thoracotomy Pain Syndrome

Summary: the investigators want to be able to show a 66% decrease in the incidence of shoulder pain in the "support" group compared to the "suspension" group.

the position currently used in cases of pulmonary lobectomies by videothoracoscopy is an extension associated with an abduction of the shoulder on the side operated by suspension of the thoracic limb in a trampoline-type arm support with an angulation of more than 90 ° of the shoulder in the saggital and frontal planes. the investigators wish to prospectively and randomly compare this position currently used in the thoracic surgery service of the iucpq with a 2nd position which seems less restrictive for all the joints of the shoulder joint complex in which the patient's arm rests on a support placed in front of the patient's face. it follows from this position of the joint degrees less than or equal to 90 ° in all planes. this new position is not experimental, but not normally used in thoracic surgery at the iucpq.

Eligibility criteria:
inclusion criteria: * any patient in whom the management of a bronchopulmonary cancer, or his strong suspicion, justifies a bilobectomy, a lobectomy or a segmentectomy by videothoracoscopy. exclusion criteria: * surgery extended to the chest wall, including extra-pleural resections, * pleurectomy, * chronic pain patient suffering from chronic pain preoperatively, * fibromyalgia patient, * chronic taking of analgesic or anti-inflammatory medications during the preoperative period, namely taking at least daily for more than 4 weeks, * patient with a history of orthopedic surgery of the upper limb ipsilateral to the surgery, * patient with mechanical limitation of the joint range of the upper limb ipsilateral to surgery, * non-french speaking patient, * pregnant woman, * patient under 18-year-old, * patient whose bmi is greater than or equal to 35 kg / m2 * glomerular filtration rate less than \<50 ml / min

Keywords: vats shoulder pain pulmonary resection
fascia iliaca blocks and pre-operative opioid requirements in hip fracture patients

Conditions: Hip Fracture

Summary: the purpose of this study is to determine if non-continuous local anesthetic fascia iliaca blocks performed in the emergency department are effective for preoperative analgesia in hip fracture patients. investigators hypothesize that patients with these blocks will have lower opioid requirements than patients in a historical group in whom blocks were not performed.


Eligibility criteria:
inclusion criteria: * low energy femoral neck and pertrochanteric-type hip fractures * age 65+ * intact cognition upon admission and ability to provide written informed consent exclusion criteria: * pathologic fractures (tumor) * high energy fractures * concomitant fractures besides hip fractures * chronic home opioid exposure prior to hospitalization * moderate to severe dementia * pre-fracture hospitalization * time from arrival to block \>6 hours * time from arrival to or \ 48 hours

Keywords: fascia iliaca blocks
exercise induced hypoalgesia diabetes

Conditions: Diabetic Peripheral Neuropathy; Diabetic Peripheral Neuropathic Pain

Summary: the purpose of this research study is to learn whether different forms of exercise can reduce pain experienced by individuals with painful diabetic peripheral neuropathy.


Eligibility criteria:
inclusion criteria: 1. subjects between the ages of 18 - 65. 2. subjects with confirmed diabetes mellitus as defined by the american diabetes association (ada), a glycosylated hemoglobin (hba1c) of 6.5%, a fasting blood glucose \> 126 mg/dl, or an oral glucose tolerance test \> 200 mg/dl. 3. subjects who have stocking and/or glove distribution neuropathy symptoms as drawn on the paindetect questionnaire. 4. subjects who have neuropathic pain as defined by a minimum score of 4 or higher on the douleur neuropathique en 4 questions (dn4). in addition, the location of pain must be present within the same region of neuropathy symptoms. 5. subjects who have an ankle brachial index (abi) between 0.7 and 1.4. exclusion criteria: 1. subjects who have pain due to some other form of neuropathy (chemo-induced neuropathy, alcohol induced neuropathy, exposure to toxins/chemicals, vitamin b12 deficiency, etc.) assessed via a medical history. 2. subjects with current or history of central nervous system disorders. 3. subjects with resting hypertension (htn) \>/= 160/90 mmhg or known uncontrolled hypertension, coronary artery disease, heart failure, retinopathy, chronic obstructive pulmonary disease, end-stage renal disease, or current open foot ulcers. 4. subjects who are unable to achieve walking a minimum distance of 400 meters in the six-minute walk test. 5. subjects with reynaud's disease or cold urticaria. 6. all vulnerable populations including adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners, individuals with cognitive impairment.
immunogenicity and tolerance of two strategies of anti-hav vaccination in hiv-infected patients

Conditions: HIV Infection

Summary: immunogenicity is reduced in immunocompromised patients. the aim of this prospective randomized study is to evaluate tolerance and immunogenicity of 2 doses versus 3 doses of anti-hav vaccine in hiv-1 infected patients with cd4 count between 200 and 500 per mm3, co-infected or not with hbv and/or hcv. the factors influencing vaccine immunogenicity will be evaluate.

recommandations for hepatitis a vaccination is the same for hiv-infected patients than for general population. however, immunogenicity induced with 2 doses of anti-hav vaccine is lower in hiv-infected patients. the primary objective of the study is to compare the immunogenicity (percentage of patients with anti-hav antibodies \> 20 mui/ml at month 7) of 2 strategies (2 doses at months 1 and 6, versus 3 doses at months 1, 2 and 6)of anti-hav vaccine in hiv-1 infected patients co-infected with hbv and/or hcv with cd4 cell count between 200 and 500/mm3. the second objectives are to compare mean anti-hav antibodies titers obtained with the 2 strategies, the durability of the seroprotection 12 months after the end of vaccination, and the safety. the paramaters than may have an effect on the immune response will be evaluated. this open, prospective, study have included 99 patients, aged from 18 to 55 years old. patients were randomized to receive 2 or 3 doses of havrix 1440 ui intramuscularly at week o, 4, and 24 or week 0, and 24. clinical and biological safety is evaluated after each immunisation and blood samples for serological evaluation taken at week -4, 4, 8, 24 and 28 for immunogenicity and week 72 for long term analysis

Eligibility criteria:
inclusion criteria: * vih-1 infection, aged 18-55 years negative anti-hav igg cd4 cell count between 200 and 500/mm3 exclusion criteria: * prior anti-hav vaccination immunosuppressive treatment splenectomy prothrombin time \ 2 uln for non co-infected patients, \> 5 uln for co-infected patients

Keywords: hiv hepatitis a vaccine hbv and/or hcv co-infection
trial comparing soc +skin iq mcm vs soc for pressure ulcer (pu)

Conditions: Pressure Ulcer

Summary: the study is a multi-center, prospective, randomized, controlled, clinical study evaluating the effects of microclimate management using skin iq™ mcm coverlet placed over commercially available pressure redistribution surfaces compared to standard of care (soc). the objective of this study is to evaluate if a commercially available pressure redistribution surface when combined with the skin iq™ mcm coverlet will significantly reduce pressure ulcer (pu) incidence as compared to use of a commercially available pressure redistribution surface by itself by decreasing the effects of excessive moisture and temperature at the skin and surface interface.

this prospective, randomized, controlled study is designed to capture, evaluate and compare the effects of skin iq™ mcm coverlet placed over commercially available pressure redistribution surfaces versus commercially available pressure redistribution surface (soc) used by itself to manage patients at risk for tissue breakdown. anticipation is that 160 subjects will need to be screened and consented to achieve the desired sample size of 136 subjects at up to 5 centers. individual subject, standard time of observation: up to 60 days for incidence of pu development; beyond 60 days, only hospital discharge date and disposition will be collected. the safety endpoint is the incidence of device-related serious adverse events (saes).

Eligibility criteria:
inclusion criteria: * subject 18 years or older * deemed at risk for tissue breakdown by clinical staff via an institutional assessment protocol such as the braden scale, the waterlow scale or the norton scale. * subject, or their legal representative, is able and willing to sign an informed consent form (icf) and willing to undergo all study related procedures. exclusion criteria: * female subjects who report being pregnant * subjects with any unstable spinal injury * subjects with chronic renal failure requiring dialysis at the time of enrollment * subjects with body mass index (bmi) \> 39 as estimated at the time of enrollment * use of hyperbaric oxygen therapy (hbo) ≤30 days prior to screening * use of external warming and/or cooling devices * subjects who have been enrolled in this study previously * subjects, who in the investigator's opinion, would have any clinically significant condition that would impair the participants' ability to comply with the study procedures * diagnosed chronic skin disorder

Keywords: pressure ulcer skin iq mcm coverlet pressure redistribution surfaces
diet oil induced stimulation of glp-1

Conditions: Type 2 Diabetes Mellitus

Summary: activation of g protein-coupled receptor gpr119 stimulates glucagon-like peptide-1 (glp-1)release from the intestinal l-cells. previously, administration of 2-oleyl-glycerol (2-og) to humans significantly increased plasma glp-1. in the present study we want to test the effect in patients with type 2 diabetes. the hypothesis is that we will expect to find a significant increased plasma glp-1 following a meal containing of 2-og when compared to meals containing of olive oil or carbohydrates alone.

activation of g protein-coupled receptor gpr119 stimulates glucagon-like peptide-1 (glp-1)release from the intestinal l-cells. previously, administration of 2-oleyl-glycerol (2-og) to humans significantly increased plasma glp-1. in the present study we want to test the effect in patients with type 2 diabetes. the hypothesis is that we will expect to find a significant increased plasma glp-1 following a meal containing of 2-og when compared to meals containing of olive oil or carbohydrates alone. the aim of the study is to elucidate the effect of 2-og, 'diet oil' on glp-1 secretion in patients with type 2 diabetes and to explain the mechanism behind the known stimulation of glp-1 release by dietary fat.

Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes mellitus according to the who criteria * caucasians * age above 18 years * bmi 20-30 exclusion criteria: * kidney disease * liver disease * retinopathy * anaemia * use of insulin * use of glp-1 analogues * use of dpp-4 inhibitors

Keywords: glucagon-like peptide-1 glucose-dependant insulinotropic polypeptide glucagon peptide pyy 2-oleyl glycerol
effects of hiit on muscle strength, atrophy and aerobic capacity in stroke patients.

Conditions: Stroke

Summary: to determine the effects of high-intensity interval training on muscle strength, atrophy, and aerobic capacity in stroke patients.


Eligibility criteria:
inclusion criteria: * both males and females were included * aged 40-60 years * chronic stroke patients who experienced a first-ever ischemic stroke * stable cardiovascular condition (american heart association class b) * physician clearance to participate in a 4-week hiit program * no prior structured exercise in the last 3 months * ability to walk 10 m over ground with or without assistive devices * patients who scored \>24/30 on mmse (mini-mental state examination) exclusion criteria: * patients who were hospitalized for cardiac or pulmonary disease within the past 3 months * patients who had implanted pacemaker or defibrillator * patients having conditions where vo2peak assessment is contraindicated, such as uncontrolled hypertension(\>180/100), severe aortic stenosis, acute myocarditis, recent myocardial infarction, or other acute cardiovascular events within the past three months, were excluded from the study * patients with severe lower limb spasticity (ashworth scale scores \>2 of 4 for knee flexion, knee extension, or ankle dorsiflexion) * pregnant females * previous exposure to fast treadmill walking in the past year

Keywords: aerobic capacity, chronic stroke, high-intensity interval training, muscle atrophy, muscle strength, stroke
the effects of immunotherapy in the nose

Conditions: Rhinitis, Allergic, Seasonal

Summary: allergic rhinitis might be caused by decreased resistance of nasal barrier to allergens and other environmental insults. about 20 % of the european population suffers from pollen allergies. birch pollen allergic rhinitis is the most common allergic disease in the scandinavia and it exists widely also in the central europe. suffering and high costs of pollen allergies may be reduced by understanding the molecular biology of the nasal barriers during allergic response. our aim is to observe the effect of season and birch pollen immunotherapy on the molecular biology of nasal epithelium and the microbiome.

this is a controlled study with an intervention arm, and a control group of healthy volunteers. the population is composed of nonsmoking healthy adults and patients having birch or timothy pollen allergy with rhinoconjuctivitis symptoms and without other diseases. the diagnosis of pollen allergy is verified with positive history, skin prick test, and allergen specific ige antibodies. subjects undergo a spirometry with a bronchodilatator test and a histamine challenge. quality of life and patient history data is collected by questionnaires. four peripheral blood samples, as well as nasal cell swabs from nasal mucosa without local anesthesia are collected from each patient; in spring and winter before the group of the intervention arm starts with birch pollen subcutaneous immunotherapy; and during the first spring and winter when a subgroups has received the birch pollen immunotherapy. we plan to perform the following analyses for the nasal specimens: transcriptomics and their regulators, sequencing of 16srrna and rt-qpcr for assessing mucosal microbiome, mass spectrometry for analyses of proteins and protein-protein complexes, immunohistochemistry for tissue level localization and quantitation of proteins, in silico analyses for the data mining, integration and display. in addition we observe the alterations in inflammatory mediators after in vitro allergen activation of purified peripheral blood leukocytes by elisa and real time qpcr.

Eligibility criteria:
inclusion criteria: * allergic rhinoconjunctivitis of birch pollen or healthy controls exclusion criteria: * smoking, asthma, any other disease than allergic rhinoconjunctivitis, requiring constant medication